At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 15 target
Drug / intervention
AlloExbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05158101Phase 1RecruitingMonitorUpdated 14mo ago · Completion was 4mo agoSlow Enrollment
Long Recruiting
Monitor
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for the Treatment of Stroke
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 15, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloEx for Stroke. Currently recruiting, targeting 15 participants across 2 sites in 2 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Stroke
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesAntigua and Barbuda, Argentina
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionFeb 2026
TodayJul 2026
First PostedDec 15, 2021
Enrollment StartFeb 1, 2022
Primary CompletionFeb 1, 2026
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 4.5 years ago
Interventions
AlloExbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes